<DOC>
	<DOCNO>NCT00382070</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use letrozole may fight breast cancer lower amount estrogen body make . It yet know whether letrozole effective placebo treat patient hormone receptor-positive breast cancer . PURPOSE : This randomized phase III trial study letrozole see well work compare placebo treat postmenopausal woman receive hormone therapy hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>Letrozole Treating Postmenopausal Women Who Have Received Hormone Therapy Hormone Receptor-Positive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether prolonged adjuvant hormonal therapy comprise letrozole v placebo improve disease-free survival postmenopausal woman estrogen receptor-positive and/or progesterone receptor-positive breast cancer complete 5 year hormonal therapy 5 year aromatase inhibitor ( AI ) 5 year combination 3 year tamoxifen citrate follow AI . - Compare disease-free survival patient treat regimen . Secondary - Compare overall survival patient treat regimen . - Compare breast cancer-free interval patient treat regimen . - Compare distant recurrence patient treat regimen . - Compare incidence osteoporotic-related fracture ( e.g. , Colles ' , hip , spine ) patient treat regimen . - Compare incidence arterial thrombotic event patient treat regimen . OUTLINE : This double-blind , multicenter , placebo-controlled , randomize study . Patients stratify accord pathologic nodal status ( negative v positive ) , adjuvant tamoxifen citrate therapy ( yes v ) , low bone mineral density T score lumbosacral spine , total hip , femoral neck ( &gt; -2.0 v â‰¤ -2.0 standard deviation ) . Patients randomize 1 2 treatment arm . - Group I : Patients receive oral placebo daily . - Group II : Patients receive oral letrozole daily . In arm , treatment continue 5 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow annually . PROJECTED ACCRUAL : A total 3,840 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Eligibility Criteria Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ( 0 = fully active , able carry predisease performance without restriction ; 1 = restrict physically strenuous activity ambulatory ) . Patients must postmenopausal time randomization . ( Note : Premenopausal perimenopausal woman require therapy luteinizing hormonereleasing hormone [ LHRH ] analog suppress ovarian function eligible . ) For study purpose , postmenopausal define : age 56 old spontaneous menses least 12 month prior study entry , age 55 young spontaneous menses least 12 month prior study entry ( e.g. , spontaneous secondary hysterectomy ) AND document estradiol level postmenopausal range accord local institutional/laboratory standard , prior document bilateral oophorectomy . The patient must remain diseasefree time initial breast cancer diagnosis time randomization . The patient must histologicallyconfirmed invasive carcinoma breast diagnostic core needle biopsy final pathologic evaluation surgical specimen . Patients receive neoadjuvant chemotherapy must clinical Stage I , II , IIIA . For patient receive adjuvant chemotherapy , primary tumor must T13 pathologic evaluation ipsilateral node must pN0 , pN1 ( pN1mi , pN1a , pN1b , pN1c ) , pN2a , pN3a , pN3b . The primary tumor must estrogen receptor ( ER ) positive and/or progesterone receptor ( PgR ) positive . ( Patients tumor consider borderline hormone receptor positivity treat tamoxifen and/or aromatases inhibitor ( AI ) eligible study . ) Patients must undergo either lumpectomy axillary nodal stag follow breast radiotherapy total mastectomy axillary nodal staging . ( Acceptable axillary nodal staging procedure include sentinel node biopsy alone , sentinel node negative hematoxylin eosin ( H &amp; E ) stain . ) The duration patient 's hormonal therapy follow breast cancer diagnosis must 5763 month first dose regardless number miss dos . Hormonal therapy must consist AI combination 3 year tamoxifen follow AI . Tamoxifen may give year 4 5 5 year adjuvant hormonal therapy . ( Note : Patients must discontinue adjuvant AI therapy time randomization . ) Optional Letrozole Registration Program patient yet complete 5 year hormonal therapy . ( Note : As September 5 , 2008 , optional NSABP B42 Registration Program close patient enrollment . Accrual data collection NSABP B42 randomize treatment trial continue plan . ) In order predominantly letrozoletreated population B42 study entry , patient minimum 2 year hormonal therapy currently tamoxifen ( 3 year ) AI may offer letrozole cost complete 5 total year initial adjuvant hormonal therapy . B42 randomization must within 6 month follow completion 5 year ( 5763 month ) initial adjuvant hormonal therapy . At time randomization , patient must follow : history physical exam within 3 month demonstrate finding suggestive recurrent breast cancer ; bilateral mammogram within 1 year ( unilateral patient mastectomy ) ; mammogram require patient prophylactic contralateral mastectomy ; bone mineral density ( BMD ) test within 1 year ; fast lipid profile ( total cholesterol , LDLC , HDLC , triglyceride ) total cholesterol value less equal grade 1 ( accord CTCAE v3.0 ) , without cholesterollowering therapy . within 1 year patient history hypercholesterolemia control cholesterollowering therapy and/or therapeutic lifestyle change patient history one following risk factor future cardiovascular event : diabetes , hypertension , obesity , tobacco use , hypertriglyceridemia , document coronary artery disease , family history premature coronary heart disease . within 2 year patient . Ineligibility Criteria Patients one follow condition ineligible study : History nontraumatic osteoporotic fracture wrist , hip , spine . Diagnosis bilateral breast cancer include ductal carcinoma situ ( DCIS ) [ ( synchronous metachronous ] . Other malignancy unless patient consider diseasefree 5 year prior randomization , deem physician low risk recurrence . Patients follow cancer eligible diagnose treat within past 5 year : carcinoma situ cervix , colon carcinoma situ , melanoma situ , basal cell squamous cell carcinoma skin . Sex hormonal therapy , e.g. , estrogen progesteronereplacement therapy oral contraceptive . These patient eligible therapy discontinue prior randomization . Therapy hormonal agent raloxifene management osteoporosis . Patients eligible medication discontinue prior study entry . Administration investigational agent within 30 day study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>